BioLife
Financials
2025 Fiscal Year Revenue
$30.05 Billion
2025 Fiscal Year Gross Profit
$16.10 Billion
2025 Fiscal Year Net Income
$709.37 Million
2025 Fiscal Year Revenue Growth
1.02%
2025 Number of Stores
275
Credit Rating
Leases are guaranteed by Baxalta, Inc. or Takeda Pharmaceuticals U.S.A., Inc, which are wholly-owned subsidiaries of Takeda Pharmaceutical Co. Ltd., which is S&P Rated: Investment Grade BBB+ (Long-Term) A-2 (Short-Term)
BioLife
BioLife Plasma Services is a subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK), specializing in the collection of high-quality plasma. This plasma is essential for the creation of therapies and treatments for various medical conditions. BioLife operates under strict safety and quality guidelines, ensuring the plasma collected is of the highest standard. Their role in the healthcare sector is significant, as they provide a critical component for the production of life-saving biopharmaceutical products. The financials and credit ratings presented are representative of the consolidated results of Takeda Pharmaceutical Company, which is BioLife Plasma Service's parent entity.